Equities

Immunovia AB (publ)

Immunovia AB (publ)

Actions
Health CareMedical Equipment and Services
  • Price (SEK)1.68
  • Today's Change-0.062 / -3.56%
  • Shares traded225.44k
  • 1 Year change-1.18%
  • Beta2.5972
Data delayed at least 15 minutes, as of Jul 04 2024 17:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.

  • Revenue in SEK (TTM)1.21m
  • Net income in SEK-260.73m
  • Incorporated2007
  • Employees11.00
  • Location
    Immunovia AB (publ)Medicon Village, Scheelevagen 8LUND 223 63SwedenSWE
  • Phone+46 462756000
  • Websitehttps://immunovia.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
iZafe Group AB5.00m-32.78m63.80m7.00--2.93--12.75-0.133-0.1330.02010.07910.1091.242.46714,857.10-71.38-52.17-82.09-69.40-10.99---655.02-487.500.6947--0.1174--149.93-24.79-36.76---41.66--
Codelab Capital AS-99.37bn-99.37bn65.92m200.00--0.4739----------0.633----------------------------0.00--------------
ProstaLund AB20.12m-18.55m68.09m6.00--0.8012--3.38-0.2436-0.24360.26380.6340.39120.432511.14---36.07-29.14-40.73-35.0171.0575.26-92.21-68.941.90-126.960.0255--27.5410.36-53.27--20.35--
Glycorex Transplantation AB (publ)31.00m-29.54m68.33m15.00--1.76--2.20-0.40-0.400.41970.54850.39780.72834.601,347,652.00-37.91-11.30-47.48-13.1784.7991.60-95.30-33.241.20-118.900.2046---17.04-2.15-254.06---0.5593--
Kontigo Care AB29.47m775.00k71.78m10.0068.272.0015.802.440.03280.03281.171.120.6807--7.69--1.79-0.42142.55-0.619568.8466.312.63-0.5205--4.000.093--1.8016.95-92.68--44.94--
BBS-Bioactive Bone Substitutes Oyj0.00-39.57m76.30m----1.25-----0.2926-0.29260.000.26470.00-------32.71-25.12-38.23-28.54-----------28.790.482-------12.64------
SciBase Holding AB (publ)24.15m-55.54m78.67m26.00--2.06--3.26-0.5255-0.52550.22370.24570.30040.78634.33894,592.60-69.07-68.63-90.03-87.7769.2861.28-229.94-300.201.78--0.00--29.9327.50-28.75--5.15--
Immunovia AB (publ)1.21m-260.73m78.89m11.00--1.81--65.09-6.06-6.060.02760.96480.007558.2314.96110,181.80-160.93-41.33-194.89-44.24-5,523.76-7,553.76-21,512.13-20,879.292.03--0.1675--37.5536.48-84.09---50.93--
Bio-Works Technologies AB43.90m-56.82m83.81m38.00--1.90--1.91-1.58-1.581.221.130.5711.825.831,155,158.00-73.91-49.14-101.72-57.9061.1069.88-129.44-168.302.79--0.00--6.2346.24-26.41--1.95--
ScandiDos AB60.43m-14.65m91.22m34.00--1.65--1.51-0.3211-0.32111.320.9710.78530.55526.07---19.03-12.60-33.80-21.9378.6982.13-24.24-15.370.9148-11.58-----1.824.36-60.62---19.29--
Scandinavian Real Heart AB0.00-71.66m92.82m11.00--0.6201-----0.4709-0.47090.000.51440.00----0.00-67.22-24.27-78.30-26.81--832.41---6,070.11---701.980.0945---100.00---385.97---25.76--
Clinical Laserthermia Systems AB10.83m-70.90m94.94m7.00--0.9486--8.77-14.73-14.731.935.790.217312.584.86---144.45-123.49-259.50-312.95-392.44-1,084.16-664.90-1,625.032.06-30.970.0094--31.9935.55-12.92--18.26--
PMD Device Solutions AB39.68m-35.45m99.66m1.00------2.51-2.06-2.064.14-5.151.58--30.16---141.30------78.66---89.34--0.0373-1.81----------------
Ortivus AB78.15m-20.63m101.72m42.00--6.29--1.30-0.4655-0.46551.760.35291.003.364.761,953,650.00-26.44-2.41-51.70-4.6333.8842.46-26.39-1.770.5256--0.4544---19.5510.00-409.66--67.43--
Luxbright AB952.90k-25.38m107.89m10.00--2.71--113.23-0.2752-0.27520.01030.36530.0265--1.9995,290.00-70.61-61.39-81.90-70.36-947.28-559.15-2,662.94-2,459.34---1,722.290.0061--73.46---20.07------
Observe Medical ASA27.77m-59.98m109.34m12.00--0.8132--3.94-1.05-1.050.48490.60630.11912.497.122,328,500.00-25.72-32.60-35.90-49.8033.2432.83-216.03-256.250.334-6.010.3204--43.14204.81-18.82--32.69--
Data as of Jul 04 2024. Currency figures normalised to Immunovia AB (publ)'s reporting currency: Swedish Krona SEK

Institutional shareholders

2.21%Per cent of shares held by top holders
HolderShares% Held
SEB Investment Management ABas of 31 May 2024307.81k0.68%
Handelsbanken Fonder ABas of 31 May 2024304.61k0.67%
Banor Capital Ltd.as of 31 Mar 2024200.00k0.44%
FCG Fonder ABas of 31 Dec 2023127.77k0.28%
Storebrand Asset Management ASas of 31 Jan 202446.50k0.10%
Skandia Investment Management ABas of 30 Apr 202412.00k0.03%
SSgA Funds Management, Inc.as of 05 Jun 2024350.000.00%
Dimensional Fund Advisors LPas of 06 Jun 202496.000.00%
More ▼
Data from 29 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.